Korean J Med.  2019 Apr;94(2):152-158. 10.3904/kjm.2019.94.2.152.

Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma

• Chae H
• Yoon DH

• KMID: 2446969
• DOI: http://doi.org/10.3904/kjm.2019.94.2.152

Abstract

CD19 chimeric antigen receptor T-cell (CAR-T) therapy, a genetically engineered cell therapy, showed unprecedented efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Two agents, axicabtagene ciloleucel and tisagenlecleucel, were approved by the Food and Drug Administration in 2017. However, CAR-T therapy is a treatment with complex logistics and high costs, as well as inherent adverse events, including cytokine-release syndrome and neurotoxicity. In addition, predictive biomarkers for efficacy and toxicity are lacking. Industry-academy cooperation is urgently required to develop CAR-T therapy that is effective, safe, and affordable for patients in Korea.

Keyword

B-cell non-Hodgkin lymphoma; Lymphoma, Large B-cell, Diffuse; Chimeric antigen receptor T-cell; CAR-T and immunotherapy

MeSH Terms

B-Lymphocytes*
Biomarkers
Cell- and Tissue-Based Therapy
Humans
Korea
Lymphoma, B-Cell*
Lymphoma, Large B-Cell, Diffuse
Organization and Administration
Receptors, Antigen*
T-Lymphocytes*
United States Food and Drug Administration
Biomarkers
Receptors, Antigen